To include your compound in the COVID-19 Resource Center, submit it here.

Sarepta to submit NDA for DMD candidate by YE

Sarepta Therapeutics Inc. (NASDAQ:SRPT) said it plans to complete submission of a rolling NDA to FDA by year end for golodirsen (SRP-4053)

Read the full 225 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE